Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Beckley Psytech

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).

2 ‘Strong Buy’ Psychedelic Stocks to Scoop Up ASAP

2 ‘Strong Buy’ Psychedelic Stocks to Scoop Up ASAP

Two psychedelic-focused stocks stand to benefit after the FDA designated psychedelics as a top review priority.

Meet the family leading the psychedelic revolution

Drug campaigner Amanda Feilding has been at the forefront of psychedelic science for half a century. Now her sons are joining the firm. Will the Beckley research empire change the way we treat mental ill health asks Alexandra Jones

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Psychedelic compound found in toads tested as alcoholism treatment

London researchers to assess possible therapeutic benefits of new synthetic drug made from mebufotenin

Evening Standard

Psychedelics M&A: Beckley Psytech Acquires Eleusis Therapeutics, Strengthening Drug Pipeline And R&D Team

Private psychedelics medicine company Beckley Psytech Ltd. has acquired 100% of clinical-stage life sciences company Eleusis Therapeutics Ltd., entitling the former to full developmental and commercial rights of the latter’s assets.

Is The UK Becoming A Global Center For Psychedelic Medicine?

This article by Freddie Earlam was originally published on Microdose and appears here with permission. If the industry-defining research already conducted at UK centers such as Imperial College, King’s college or even Exeter University’s recent Ketamine Research isn’t enough to convince you, then two more crucial factors surely will. Firstly, a new ‘accelerated pathway’ has…

These Private Psychedelics Companies Have Raised Impressive Amounts Of Money

Throughout the last decade, more and more companies have popped up that are focused on discovering and developing psychedelic compounds to revolutionize the treatment of mental illness. A number of these companies, including Atai Life Sciences (NASDAQ:ATAI) and Compass Pathways (NASDAQ:CMPS) are already publicly traded. But today we will take a…

inkl

Read news from The Economist, FT, and more,
with one subscription

Psyched: UK Streamlines MDMA Therapy, FDA OKs MindMed's First LSD Trial In 40 years, Atai Launches Subsidiary

Psyched: UK Streamlines MDMA Therapy, FDA OKs MindMed's First LSD Trial In 40 years, Atai Launches Subsidiary

The Week In Psychedelics

Beckley Psytech Begins Training Therapists For Phase 2 Trial With Toad Venom, 5-MeO-DMT

Beckley Psytech Begins Training Therapists For Phase 2 Trial With Toad Venom, 5-MeO-DMT

Beckley Psytech, a private company in the psychedelics space, announced that it has begun training psychotherapists for a Phase 2 clinical trial with 5-MeO-DMT, a strong and fast-acting psychedeli

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Imperial College

Compass Pathways

Exeter University

ATAI Life Sciences

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

311,170 stories

124,377 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play